BR0210771A - Métodos para selecionar uma sequência de dna com uma qualidade moduladora da transcrição de gene, para identificar uma sequência de dna com uma qualidade repressora da transcrição de gene, para detectar a presença de uma sequência star e de um elemento star dentro de uma sequência de ácido nucleico, para determinar se uma sequência de ácido nucleico compreende uma sequência star, e, para produzir um produto de gene em uma célula, sequência de ácido nucleico isolada e/ou recombinante, sequência de dna, sequência star, coleção, construção de dna, uso de uma construção ou sequência de dna, e, biblioteca de ácidos nucleicos isolados e/ou recombinantes - Google Patents

Métodos para selecionar uma sequência de dna com uma qualidade moduladora da transcrição de gene, para identificar uma sequência de dna com uma qualidade repressora da transcrição de gene, para detectar a presença de uma sequência star e de um elemento star dentro de uma sequência de ácido nucleico, para determinar se uma sequência de ácido nucleico compreende uma sequência star, e, para produzir um produto de gene em uma célula, sequência de ácido nucleico isolada e/ou recombinante, sequência de dna, sequência star, coleção, construção de dna, uso de uma construção ou sequência de dna, e, biblioteca de ácidos nucleicos isolados e/ou recombinantes

Info

Publication number
BR0210771A
BR0210771A BR0210771-6A BR0210771A BR0210771A BR 0210771 A BR0210771 A BR 0210771A BR 0210771 A BR0210771 A BR 0210771A BR 0210771 A BR0210771 A BR 0210771A
Authority
BR
Brazil
Prior art keywords
sequence
nucleic acid
star
dna
acid sequence
Prior art date
Application number
BR0210771-6A
Other languages
English (en)
Other versions
BRPI0210771B8 (pt
BRPI0210771B1 (pt
Inventor
Arie Pieter Otte
Arthur Leo Kruckeberg
Original Assignee
Chromagenics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202581A external-priority patent/EP1273666A1/en
Application filed by Chromagenics Bv filed Critical Chromagenics Bv
Publication of BR0210771A publication Critical patent/BR0210771A/pt
Publication of BRPI0210771B1 publication Critical patent/BRPI0210771B1/pt
Publication of BRPI0210771B8 publication Critical patent/BRPI0210771B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODOS PARA SELECIONAR UMA SEQuêNCIA DE DNA COM UMA QUALIDADE MODULADORA DA TRANSCRIçãO DE GENE, PARA IDENTIFICAR UMA SEQuêNCIA DE DNA COM UMA QUALIDADE REPRESSORA DA TRANSCRIçãO DE GENE, PARA DETECTAR A PRESENçA DE UMA SEQuêNCIA STAR E DE UM ELEMENTO STAR DENTRO DE UMA SEQuêNCIA DE áCIDO NUCLEICO, PARA DETERMINAR SE UMA SEQuêNCIA DE áCIDO NUCLEICO COMPREENDE UMA SEQuêNCIA STAR, E, PARA PRODUZIR UM PRODUTO DE GENE EM UMA CéLULA, SEQuêNCIA DE áCIDO NUCLEICO ISOLADA E/OU RECOMBINANTE, SEQuêNCIA DE DNA, SEQuêNCIA STAR, COLEçãO, CONSTRUçãO DE DNA, USO DE UMA CONSTRUçãO OU SEQuêNCIA DE DNA, E, BIBLIOTECA DE áCIDOS NUCLEICOS ISOLADOS E/OU RECOMBINANTES". A invenção diz respeito à elucidação e identificação sistemáticas de seq³ências reguladoras. A invenção fornece entre outros métodos de triagens e detecção com os quais as seq³ências reguladoras podem ser identificadas. A invenção ainda fornece seq³ências reguladoras e o uso destas em vários campos tais como, mas não limitados à produção de proteína, diagnósticos, plantas transgênicas e animais e ao campo terapêutico.
BRPI0210771A 2001-07-04 2002-06-14 construção de dna recombinante, método para a produção de um produto de gene em uma célula, e, uso de uma sequência de dna BRPI0210771B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01202581A EP1273666A1 (en) 2001-07-04 2001-07-04 Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
US30319901P 2001-07-05 2001-07-05
PCT/NL2002/000390 WO2003004704A2 (en) 2001-07-04 2002-06-14 Method of selecting dna sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
US10/190,312 US7192741B2 (en) 2001-07-04 2002-07-05 DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences

Publications (3)

Publication Number Publication Date
BR0210771A true BR0210771A (pt) 2004-07-13
BRPI0210771B1 BRPI0210771B1 (pt) 2015-12-22
BRPI0210771B8 BRPI0210771B8 (pt) 2021-05-25

Family

ID=47915807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210771A BRPI0210771B8 (pt) 2001-07-04 2002-06-14 construção de dna recombinante, método para a produção de um produto de gene em uma célula, e, uso de uma sequência de dna

Country Status (21)

Country Link
US (9) US7192741B2 (pt)
EP (8) EP1404872B1 (pt)
JP (3) JP4500044B2 (pt)
KR (2) KR100942117B1 (pt)
CN (1) CN1266282C (pt)
AT (8) ATE466941T1 (pt)
AU (3) AU2002314629B2 (pt)
BR (1) BRPI0210771B8 (pt)
CA (2) CA2450020C (pt)
CY (1) CY1107678T1 (pt)
DE (8) DE60237048D1 (pt)
DK (8) DK1842919T3 (pt)
ES (8) ES2348174T3 (pt)
IL (4) IL159674A0 (pt)
MX (1) MXPA03011801A (pt)
NO (1) NO338477B1 (pt)
NZ (1) NZ530218A (pt)
PT (1) PT1600510E (pt)
SG (1) SG143066A1 (pt)
WO (1) WO2003004704A2 (pt)
ZA (1) ZA200309599B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466941T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
CA2489475C (en) 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
AU2003243059A1 (en) 2002-06-14 2003-12-31 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP1573058B1 (en) 2002-12-18 2011-09-14 ChromaGenics B.V. A method for improving protein production
ATE354645T1 (de) 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
HRP20130616T1 (en) 2003-10-02 2013-08-31 Crucell Holland B.V. Packaging cells for recombinant adenovirus
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
PT1763586E (pt) * 2004-07-08 2008-02-25 Chromagenics Bv Nova sequência para melhorar a expressão de ácido nucleico
ATE459720T1 (de) * 2004-08-18 2010-03-15 Bayer Cropscience Ag Pflanzen mit erhöhter plastidär aktivität der stärkephosphorylierenden r3-enzyme
EP1809750B1 (en) 2004-11-08 2012-03-21 ChromaGenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060172382A1 (en) * 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP1820856B1 (en) * 2004-11-18 2011-04-27 National University of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US7968700B2 (en) 2006-03-20 2011-06-28 Chromagenics B.V. Expression augmenting DNA fragments, use thereof, and methods for finding thereof
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
JP2010515435A (ja) * 2007-01-08 2010-05-13 ミリポア・コーポレイション 遺伝子増幅を不要とする高発現細胞株
EP2443239B1 (en) 2009-06-15 2015-11-25 Cellagenics B.V. Novel stringent selectable markers
US8566596B2 (en) 2010-08-24 2013-10-22 Cisco Technology, Inc. Pre-association mechanism to provide detailed description of wireless services
CN103180443B (zh) 2010-09-01 2016-01-13 萨拉基尼克有限公司 用于增强基因表达的来自核糖体蛋白启动子的核酸片段
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
US10417380B1 (en) 2013-12-31 2019-09-17 Mckesson Corporation Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber
US10489552B2 (en) 2014-02-14 2019-11-26 Mckesson Corporation Systems and methods for determining and communicating patient incentive information to a prescriber
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
US10157262B1 (en) 2015-03-10 2018-12-18 Mckesson Corporation Systems and methods for determining patient financial responsibility for multiple prescription products
SI3115376T1 (sl) 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
US11514137B1 (en) 2016-03-30 2022-11-29 Mckesson Corporation Alternative therapy identification system
US10999224B1 (en) 2017-02-01 2021-05-04 Mckesson Corporation Method and apparatus for parsing an electronic message and constructing multiple differently prioritized messages therefrom
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
US10862832B1 (en) 2018-07-24 2020-12-08 Mckesson Corporation Computing system and method for automatically reversing an action indicated by an electronic message
US11043437B2 (en) 2019-01-07 2021-06-22 Applied Materials, Inc. Transparent substrate with light blocking edge exclusion zone
US12469040B1 (en) 2019-06-26 2025-11-11 Mckesson Corporation Method, apparatus, and computer program product for providing real-time pricing information
US11562437B1 (en) 2019-06-26 2023-01-24 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US11636548B1 (en) 2019-06-26 2023-04-25 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US12525327B1 (en) 2019-06-26 2026-01-13 Mckesson Corporation Method, apparatus, and computer program product for providing real-time pricing information
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
WO2021155369A1 (en) * 2020-01-31 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to identify genetic silencers and applications thereof
US12229833B1 (en) 2020-02-17 2025-02-18 Mckesson Corporation Method, apparatus, and computer program product for reformatting an electronic prescription transaction
US12229834B1 (en) 2020-02-17 2025-02-18 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
US11610240B1 (en) 2020-02-17 2023-03-21 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
MX2022014208A (es) 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
US11587657B2 (en) 2020-09-04 2023-02-21 Mckesson Corporation Method, apparatus, and computer program product for performing an alternative evaluation procedure in response to an electronic message
US12367954B1 (en) 2021-01-08 2025-07-22 Mckesson Corporation Method, apparatus, and computer program product for estimating a target quantitative measure based upon historical electronic messages
US12518304B1 (en) 2021-01-26 2026-01-06 Mckesson Corporation Method, apparatus, and computer program product for estimating a target quantitative measure based upon historical electronic messages
CN113539357B (zh) * 2021-06-10 2024-04-30 阿里巴巴达摩院(杭州)科技有限公司 基因检测方法、模型训练方法、装置、设备及系统
US12197972B1 (en) 2022-03-28 2025-01-14 Mckesson Corporation Method, apparatus, and computer program product for generating alternative evaluation messages

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US719271A (en) * 1902-01-13 1903-01-27 Solomon P Smith Furnace.
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5972605A (en) 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
CA2216428A1 (en) * 1995-03-24 1996-10-03 Shionogi & Co., Ltd. Dna molecule relating to suppression of gene expression and novel protein
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6037525A (en) * 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100365127C (zh) 1998-07-21 2008-01-30 密理博公司 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
DK1104490T3 (da) * 1998-08-14 2008-01-02 Chromagenics Bv Fremgangsmåde til påvisning af en DNA-sekvens, DNA-sekvens, fremgangsmåde til fremstilling af en DNA-konstruktion samt anvendelse deraf
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU1128400A (en) 1998-10-22 2000-05-08 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
WO2001014529A1 (en) * 1999-08-25 2001-03-01 Immunex Corporation Compositions and methods for improved cell culture
US20030166042A1 (en) 2000-02-11 2003-09-04 Millennium Pharmaceuticals, Inc. Novel seven-transmembrane proteins/G-protein coupled receptors
US6586205B1 (en) 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
EP1430124B1 (en) 2000-09-20 2013-11-06 EMD Millipore Corporation Artificial ubiquitous chromatin opening elements (ucoe)
ATE466941T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
EP1273666A1 (en) 2001-07-04 2003-01-08 Chromagenics B.V. Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
AU2003243059A1 (en) 2002-06-14 2003-12-31 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
CA2489475C (en) * 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
EP1573058B1 (en) 2002-12-18 2011-09-14 ChromaGenics B.V. A method for improving protein production
ATE354645T1 (de) 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können

Also Published As

Publication number Publication date
IL193373A (en) 2010-12-30
EP1845162A1 (en) 2007-10-17
ATE466944T1 (de) 2010-05-15
AU2007234619A1 (en) 2007-12-13
US7749733B2 (en) 2010-07-06
EP1829972B1 (en) 2010-05-12
US7655441B2 (en) 2010-02-02
MXPA03011801A (es) 2005-03-07
HK1068652A1 (en) 2005-04-29
US7659094B2 (en) 2010-02-09
CA2812799C (en) 2016-01-26
EP1600510B1 (en) 2007-03-28
EP1806407B1 (en) 2010-05-05
EP1404872B1 (en) 2006-10-18
CN1266282C (zh) 2006-07-26
ES2344071T3 (es) 2010-08-17
IL159674A0 (en) 2004-06-20
US7951586B2 (en) 2011-05-31
NZ530218A (en) 2005-09-30
ATE343004T1 (de) 2006-11-15
DE60236379D1 (de) 2010-06-24
US20070128717A1 (en) 2007-06-07
EP1829972A3 (en) 2007-10-24
EP1808488A3 (en) 2007-11-14
CA2812799A1 (en) 2003-01-16
NO338477B1 (no) 2016-08-22
ZA200309599B (en) 2006-05-31
DK1845162T3 (da) 2010-08-16
ES2274045T3 (es) 2007-05-16
DE60236331D1 (de) 2010-06-17
WO2003004704A3 (en) 2003-10-16
CN1524128A (zh) 2004-08-25
EP1600510A3 (en) 2006-02-22
PT1600510E (pt) 2007-06-25
EP1600510A2 (en) 2005-11-30
CY1107678T1 (el) 2013-04-18
DE60236334D1 (de) 2010-06-17
ATE474053T1 (de) 2010-07-15
EP1845162B1 (en) 2010-05-05
US20070026499A1 (en) 2007-02-01
EP1808488B1 (en) 2010-07-14
IL193374A (en) 2010-12-30
DE60219221T2 (de) 2008-01-03
JP2010131024A (ja) 2010-06-17
JP2004533262A (ja) 2004-11-04
ES2285630T3 (es) 2007-11-16
US20030199468A1 (en) 2003-10-23
AU2011202193B2 (en) 2011-09-29
ES2344074T3 (es) 2010-08-17
EP1404872A2 (en) 2004-04-07
DK1829972T3 (da) 2010-09-13
EP1808488A2 (en) 2007-07-18
ES2344073T3 (es) 2010-08-17
ATE466943T1 (de) 2010-05-15
SG143066A1 (en) 2008-06-27
AU2011202193A1 (en) 2011-06-02
DE60215502D1 (de) 2006-11-30
AU2007234619B2 (en) 2011-06-02
EP1842919B1 (en) 2010-05-05
EP1806407A2 (en) 2007-07-11
US20070031935A1 (en) 2007-02-08
US7736868B2 (en) 2010-06-15
DE60236333D1 (de) 2010-06-17
ATE466941T1 (de) 2010-05-15
AU2002314629B2 (en) 2007-08-30
US20070031936A1 (en) 2007-02-08
ES2344072T3 (es) 2010-08-17
JP5014444B2 (ja) 2012-08-29
EP1829971B1 (en) 2010-05-05
DK1808488T3 (da) 2010-10-18
ATE467682T1 (de) 2010-05-15
JP4500044B2 (ja) 2010-07-14
DK1600510T3 (da) 2007-06-25
EP1829972A2 (en) 2007-09-05
US7662591B2 (en) 2010-02-16
NO20040011L (no) 2004-03-03
US7736869B2 (en) 2010-06-15
US20070037256A1 (en) 2007-02-15
US7736870B2 (en) 2010-06-15
DK1806407T3 (da) 2010-08-16
DK1829971T3 (da) 2010-08-16
KR100942116B1 (ko) 2010-02-12
KR100942117B1 (ko) 2010-02-12
BRPI0210771B8 (pt) 2021-05-25
US7192741B2 (en) 2007-03-20
JP2010131025A (ja) 2010-06-17
WO2003004704A2 (en) 2003-01-16
DE60215502T2 (de) 2007-08-30
CA2450020C (en) 2013-08-13
ES2344070T3 (es) 2010-08-17
ES2348174T3 (es) 2010-11-30
US20070031934A1 (en) 2007-02-08
EP1829971A3 (en) 2008-06-04
US20070026498A1 (en) 2007-02-01
KR20090037960A (ko) 2009-04-16
DE60237048D1 (de) 2010-08-26
DE60236332D1 (de) 2010-06-17
US20070031933A1 (en) 2007-02-08
DK1404872T3 (da) 2007-02-19
EP1829971A1 (en) 2007-09-05
ATE358183T1 (de) 2007-04-15
EP1842919A1 (en) 2007-10-10
BRPI0210771B1 (pt) 2015-12-22
DE60219221D1 (de) 2007-05-10
CA2450020A1 (en) 2003-01-16
IL159674A (en) 2009-02-11
DK1842919T3 (da) 2010-08-16
KR20090037485A (ko) 2009-04-15
JP5014443B2 (ja) 2012-08-29
ATE466942T1 (de) 2010-05-15
EP1806407A3 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
BR0210771A (pt) Métodos para selecionar uma sequência de dna com uma qualidade moduladora da transcrição de gene, para identificar uma sequência de dna com uma qualidade repressora da transcrição de gene, para detectar a presença de uma sequência star e de um elemento star dentro de uma sequência de ácido nucleico, para determinar se uma sequência de ácido nucleico compreende uma sequência star, e, para produzir um produto de gene em uma célula, sequência de ácido nucleico isolada e/ou recombinante, sequência de dna, sequência star, coleção, construção de dna, uso de uma construção ou sequência de dna, e, biblioteca de ácidos nucleicos isolados e/ou recombinantes
Joazeiro Ribosomal stalling during translation: providing substrates for ribosome-associated protein quality control
Wang et al. Interorganellar regulation of lysosome positioning by the Golgi apparatus through Rab34 interaction with Rab-interacting lysosomal protein
Vucetic et al. Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions
Bouwman et al. Endogenous DNA double-strand breaks during DNA transactions: emerging insights and methods for genome-wide profiling
Crawford et al. Caspase substrates and cellular remodeling
Gaze et al. An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas
NO974964L (no) Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse
Lee et al. Proteome-wide discovery of mislocated proteins in cancer
Kawalek et al. Rules and exceptions: the role of chromosomal ParB in DNA segregation and other cellular processes
JP6293742B2 (ja) デザイナーモノヌクレオソーム（ｄｅｓｉｇｎｅｒｍｏｎｏｎｕｃｌｅｏｓｏｍｅ）のＤＮＡバーコード化ならびにクロマチンリーダー、ライター、イレーサーおよびそのモジュレーターをプロファイリングするためのクロマチンアレイライブラリー
EP4574992A3 (en) Combinatorial dna screening
WO2003074734A3 (en) Methods for detecting genome-wide sequence variations associated with a phenotype
JPH09508800A (ja) 差次的発現遺伝子の同定法
SE0003286D0 (sv) Method and kit for human identification
Guo et al. Genome-wide antagonism between 5-hydroxymethylcytosine and DNA methylation in the adult mouse brain
PT750672E (pt) Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao.
Alzan et al. Comparative bioinformatics analysis of transcription factor genes indicates conservation of key regulatory domains among Babesia bovis, Babesia microti, and Theileria equi
Bhagwat et al. Proteolysis to identify protease substrates: Cleave to decipher
Zhang et al. Programmable sequence-specific transcriptional regulation of mammalian genome using designer TAL effectors
ATE440967T1 (de) Auswahl von tieren für gewünschte genotypische und potentielle phänotypische eigenschaften auf der basis eines einzelnen nukleotidpolymorphismus (snp) im intron 3 des igf2-gens
Shin et al. Development of multiplexed immuno-N-terminomics to reveal the landscape of proteolytic processing in early embryogenesis of drosophila melanogaster
BR9806183A (pt) Quinases de proteìna e usos das mesmas
Palermo et al. Expression profiling Smackdown: human transcriptome Array HTA 2.0 vs. RNA-Seq
Loit et al. Functional whole-colony screening method to identify antimicrobial peptides

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2726 DE 04/04/2023 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/06/2022